Page 1

• • • BLACK DIAMOND THERAPEUTICS Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey - 01 study of BDTX - 189 this year Pre - clinical data from BDTX - 1535 , BRAF , and FGFR programs presented at AACR - NCI - EORTC ( ANE ) International Conference Strategic partnership established with OpenEye to accelerate drug discovery efforts through cloud - based molecular dynamics technology Cash , cash equivalents , and investments of $ 235.0 million as of September 30 , 2021 , expected to be sufficient to fund operations into the second half of 2023 CAMBRIDGE , Mass . and NEW YORK , November 8 , 2021 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics , Inc. ( Nasdaq : BDTX ) , a precision oncology medicine company pioneering the discovery and development of MasterKey therapies , today reported financial results for the third quarter ended September 30 , 2021 and provided a corporate update . " Black Diamond's approach remains deeply rooted in our proprietary Mutation - Allostery - Pharmacology ( MAP ) drug discovery engine , which leverages population - level genetic sequencing that allows for the identification of novel oncogenic mutations . We are well - positioned to advance differentiated MasterKey programs across a range of oncogenic targets for patient populations with unmet need , ” said David Epstein , Ph.D. , President and Chief Executive Officer of Black Diamond Therapeutics . " We are excited by the continued development and advancement of our pipeline of MasterKey inhibitor programs , including the BDTX - 189 MasterKey - 01 study , our BDTX - 1535 program with an IND filing anticipated by the first half of 2022 , and our BRAF and fibroblast growth factor receptor ( FGFR ) programs . " Recent Developments BDTX - 189 : • Black Diamond remains on track with preparations for initiating the Phase 2 portion of the MasterKey - 01 Phase 1/2 study of BDTX - 189 by the end of 2021. The Company completed the Phase 1 dose - escalation portion of the study and has selected the recommended Phase 2 dose for BDTX - 189 . BDTX - 1535 : • • Black Diamond continues to advance BDTX - 1535 through IND - enabling studies and expects to file an IND application by the first half of 2022 . In October 2021 , Black Diamond presented preclinical data for BDTX - 1535 at the ANE International Conference :